My watch list
my.bionity.com  
Login  

2,007 Newest Publications in oncogene

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment

24-May-2018 | P. Xiao; Y. Guo; H. Zhang; X. Zhang; H. Cheng; Q. Cao; Y. Ke, Oncogene, 2018

The Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp2) is generally considered to be an oncogene owing to its ability in enhancing the malignancy of multiple types of tumor cells; however, its role in modulating tumor immunity remains largely elusive. Here, we reported that ...

more

Artemisitene suppresses tumorigenesis by inducing DNA damage through deregulating c-Myc-topoisomerase pathway

24-May-2018 | Jian Chen; Wenjuan Li; Ke Cui; Kaiyuan Ji; Shuxiang Xu; Yang Xu, Oncogene, 2018

Cancer chemotherapeutic agents such as doxorubicin are DNA damage inducers that also kill normal cells, making them highly toxic to cancer patients. To improve the efficacy and safety of chemotherapy, it is important to develop new chemotherapeutic agents that selectively kill cancer cells. Here ...

more

Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network

23-May-2018 | Jie Ding; Chiuan-Ren Yeh; Yin Sun; Changyi Lin; Joshua Chou; Zhenyu Ou; Chawnshang Chang; Jun Qi; Shuyuan Yeh, Oncogene, 2018

Recent studies indicated that the estrogen receptor beta (ERβ) could affect the progression of prostate and bladder tumors, however, its roles in the renal cell carcinoma (RCC), remain to be elucidated. Here, we provide clinical evidence that ERβ expression is correlated in a negative manner with ...

more

Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin

23-May-2018 | Souleymane Abdoul-Azize; Catherine Buquet; Hong Li; Jean-Michel Picquenot; Jean-Pierre Vannier, Oncogene, 2018

Recent studies have suggested that the lipid-lowering agent simvastatin holds great promise as a cancer therapeutic; it inhibits the growth of multiple tumors, including triple-negative breast cancer. Doxorubicin- and simvastatin-induced cytotoxicity has been associated with the modulation of ...

more

Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer

23-May-2018 | Tong-peng Xu; Wen-yu Wang; Pei Ma; You Shuai; Kun Zhao; Yan-fen Wang; Wei Li; Rui Xia; Wen-ming Chen; Er-bao Zhang; ..., Oncogene, 2018

Accumulating data indicate that long noncoding RNAs (lncRNAs) serve as important modulators in biological processes and are dysregulated in diverse tumors. The function of FOXD2-AS1 in gastric cancer (GC) progression and related biological mechanisms remain undefined. A comprehensive analysis ...

more

Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer

23-May-2018 | Weilin Li; Jennifer Mun-Kar Ng; Chi Chun Wong; Enders Kwok Wai Ng; Jun Yu, Oncogene, 2018

The term metastasis is widely used to describe the endpoint of the process by which tumour cells spread from the primary location to an anatomically distant site. Achieving successful dissemination is dependent not only on the molecular alterations of the cancer cells themselves, but also on the ...

more

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

23-May-2018 | Mary E. Klein; Mark A. Dickson; Cristina Antonescu; Li-Xuan Qin; Scott J. Dooley; Afsar Barlas; Katia Manova; Gary K ..., Oncogene, 2018

CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein. The downregulation of MDM2 following treatment with CDK4/6 inhibitors also ...

more

Shared and independent functions of aPKCλ and Par3 in skin tumorigenesis

23-May-2018 | Susanne Vorhagen; Dominik Kleefisch; Oana-Diana Persa; Annika Graband; Alexandra Schwickert; Michael Saynisch; Micha ..., Oncogene, 2018

The polarity proteins Par3 and aPKC are key regulators of processes altered in cancer. Par3/aPKC are thought to dynamically interact with Par6 but increasing evidence suggests that aPKC and Par3 also exert complex-independent functions. Whereas aPKCλ serves as tumor promotor, Par3 can either ...

more

Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer

21-May-2018 | Anne Serrao; Laura M. Jenkins; Alexander A. Chumanevich; Ben Horst; Jiaxin Liang; Michael L. Gatza; Nam Y. Lee; Igor ..., Oncogene, 2018

CDK8 is a transcription-regulating kinase that controls TGF-β/BMP-responsive SMAD transcriptional activation and turnover through YAP1 recruitment. However, how the CDK8/YAP1 pathway influences SMAD1 response in cancer remains unclear. Here we report that SMAD1-driven epithelial-to-mesenchymal ...

more

E-cadherin in contact inhibition and cancer

21-May-2018 | Alisha M. Mendonsa; Tae-Young Na; Barry M. Gumbiner, Oncogene, 2018

E-cadherin is a key component of the adherens junctions that are integral in cell adhesion and maintaining epithelial phenotype of cells. Homophilic E-cadherin binding between cells is important in mediating contact inhibition of proliferation when cells reach confluence. Loss of E-cadherin ...

more

Page 1 From 201
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE